TEI 9826Alternative Names: Free acid of TOK 4528; Lipo-TEI 9826
Latest Information Update: 19 Oct 2000
At a glance
- Originator Teijin Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Oct 2000 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 20 Jun 2000 A preclinical study has been added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections
- 24 Feb 2000 A preclinical study has been added to the pharmacokinetics and Cancer pharmacodynamics sections